Advertisement

Übersichtstabellen

  • O. Dietmaier
  • G. Laux

Zusammenfassung

In diesen Tabellen sind die in Deutschland (D), Österreich (A) und der Schweiz (CH) im Handel erhältlichen Parkinsonmittel und etablierten Antidementiva (Nootropika) alphabetisch nach ihren gebräuchlichen Kurzbezeichnungen aufgeführt. Es wurden die in der Roten Liste 1999 verwandten internationalen Freinamen (INN), INNv (vorgeschlagene Freinamen) oder sonstige Kurzbezeichnungen gewählt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abate G, Angeleri F, Bartorelli L, Battistin L et al. (1992) Epidemiologische Studie zur Wirksamkeit Und Verträglichkeit von Dihydroergo-cristin bei Verschlechterung der Gedächtnis-und der Verhaltensfunktionen beim älteren Menschen. Arzneimittelforschung/Drug Res 42: 1417–1421Google Scholar
  2. Anand R, Gharabawi G (1996) Clinical development of Exelon registered (ENA713): the ADENA registered programme. J Drug Dev ClinPract 8: 117–122Google Scholar
  3. Auberger S, Greil W, Rüther E (1985) Tiapride in the treatment of tardive dyskinesia. A double-blind study. Pharmacopsychiatry 18: 61–62CrossRefGoogle Scholar
  4. Barnes TRE, Mcphillips MA (1996) Antipsychotic-induced extrapyramidal symptoms. Role of anticholinergic drugs in treatment. CNS Drugs 6: 315–330CrossRefGoogle Scholar
  5. Barradell LB, Brogden RN (1996) Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322PubMedCrossRefGoogle Scholar
  6. Bassi S, Albizzati MG, Calloni E et al. (1986) Treatment of Parkinson’s disease with orphenadrine alone and in combination with L-dopa. Br J Clin Pract 40: 273–275PubMedGoogle Scholar
  7. Battistin L, Meneghetti G, Rigotti S et al. (1978) Long-term treatment of Parkinson’s disease with L-dopa and dopa-decarboxylase inhibitor: therapeutic results and side effects. Acta Neurol Scand 57: 186–192PubMedCrossRefGoogle Scholar
  8. Bayer AJ, Bokonjic R, Booya NH, Demarin V et al. (1996) European pentoxifylline multiinfarct dementia study. Eur Neurol 36: 315–321CrossRefGoogle Scholar
  9. Block G, Liss C, Reines S, Irv J et al. (1997) Comparison of immediate-release and controlled release Carbidopa/Levodopa in Parkinson’s disease. A multicenter 5-year study. Eur Neurol 37: 23–27PubMedCrossRefGoogle Scholar
  10. Bosch MF, Ludin HP (1994) Apomorphin als adjuvante Behandlung beim idiopathischen Parkinsonsyndrom. Schweiz Arch Neurol Psychiatr 145: 8–13PubMedGoogle Scholar
  11. Bryson HM, Benfield P (1997) Donepezil. Drugs Aging 10: 234–241PubMedCrossRefGoogle Scholar
  12. Chouinard G, Annable L, Mercier P, Turnier L (1987) Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 23: 221–226PubMedGoogle Scholar
  13. Danielczyk W (1995) Twenty-five years of amantadine therapy in Parkinson’s disease. J Neural Transm 46 [Suppl]: 399–405Google Scholar
  14. Danielczyk W, Schnaberth G (1995) Anticholinergika. Stellenwert in der modernen Parkinsontherapie. Neuropsychiatrie 9 [Suppl 1]: 25–26Google Scholar
  15. Dechant KL, Plosker GL (1997) Ropinirole. CNS Drugs 8: 335–341CrossRefGoogle Scholar
  16. Deffond D, Durif F, Tournilhac M (1993) Apomorphine in treatment of Parkinson’s disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 56: 101–103PubMedCrossRefGoogle Scholar
  17. Deuschl G (Hrsg) (1995) Morbus Parkinson. Dihydroergocryptin — ein neuer Dopamin-Agonist. Thieme, Stuttgart New YorkGoogle Scholar
  18. Dingemanse J, Kleinbloesem CH, Zürcher G, Woods ND et al. (1997) Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 44: 41–48PubMedCrossRefGoogle Scholar
  19. Fariello RG (1998) Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson’s disease. Drugs 55 [Suppl 1]: 10–16PubMedCrossRefGoogle Scholar
  20. Fischer PA, Frieling B (Hrsg) (1989) Morbus Parkinson — neue Möglichkeiten mit Lisurid. De Gruyter, Berlin New YorkGoogle Scholar
  21. Fischer PA, Przuntek H, Majer M, Welzel D (1984) Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Dtsch Med Wochenschr 109: 1279–1283PubMedCrossRefGoogle Scholar
  22. Fischhof PK, Saletu B, Rüther E, Litschauer G et al. (1992) Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 26: 65–70PubMedCrossRefGoogle Scholar
  23. Fischhof PK, Moslinger-Gehmayr R, Herrmann WH, Friedmann A et al. (1996) Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 34: 29–35PubMedCrossRefGoogle Scholar
  24. Fulton B, Benfield P (1996) Galanthamine. Drugs Aging 9: 60–65PubMedCrossRefGoogle Scholar
  25. Ghika J, Gachoud JP, Gasser U, Beck-Fohn M et al. (1997) Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. Clin Neuropharmacol 20: 130–139PubMedCrossRefGoogle Scholar
  26. Görtelmeyer R, Erbler H (1992) Memantine in treatment of mild to moderate dementia syndrome. Drug Res 42: 904–913Google Scholar
  27. Gouliaev AH, Senning A (1994) Piracetam and other structurally related nootropics. Brain Res Rev 19: 180–222PubMedCrossRefGoogle Scholar
  28. Grossmann WM, Standl A, May U, Van Laak HH et al. (1991) Naftidrofuryl in the treatment of mild senile dementia. Pharmacopsychiatry 23: 265–273CrossRefGoogle Scholar
  29. Gutzmann H, Kuhl KP, Kanowski S, Khan-Boluki J (1997) Measuring the efficacy of psycho-pharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry 30: 6–11PubMedCrossRefGoogle Scholar
  30. Ham RJ (1997) Clinical efficacy of donepezil hydrochloride in patients with Alzheimer’s disease: case studies. Adv Ther 14: 223–233Google Scholar
  31. Harris SJ, Dowson JH (1986) The effects of meclofenoxate on cognitive performance in elderly individuals with memory impairment: a placebo-controlled study. Int J Geriatr Psychiatry 1: 93–98CrossRefGoogle Scholar
  32. Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of nicer-goline in patients with multi-infarct dementia. Dementia Geriatr Cogn Disord 8: 9–17CrossRefGoogle Scholar
  33. Imbimbo BP, Licini M, Schettino M, Mosca A et al. (1995) Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 35: 285–290PubMedGoogle Scholar
  34. Itil TM, Eralp E, Tsambis E, Itil KZ et al. (1996) Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 3: 63–73PubMedCrossRefGoogle Scholar
  35. Jabbari B, Scherokman B, Gunderson CH, Rosenberg ML et al. (1989) Treatment of movement disorders with trihexyphenidyl. Mov Disord 4: 202–212PubMedCrossRefGoogle Scholar
  36. Jörg J, Pröfrock A (1995) Wirksamkeit und Verträglichkeit der Parkinson-Behandlung mit Amantadinsulfat. Nervenheilkunde 14: 76–82Google Scholar
  37. Kanowski S, Herrmann WM, Stephan K, Wierich W et al. (1996) Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry 29: 47–56PubMedCrossRefGoogle Scholar
  38. Kiss B, Karpatt E (1996) On the mechanism of action of vinpocetine. Acta Pharm Hung 66: 213–224PubMedGoogle Scholar
  39. Klein HE, Kubber S (1995) Kalziumantagonisten bei dementiellen Erkrankungen. Eine Erhebung zur therapeutischen Wirksamkeit. Münch Med Wochenschr 137: 38–43Google Scholar
  40. Klockgether T, Wullner U, Steinbach JP, Petersen V et al. (1996) Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301: 67–73PubMedCrossRefGoogle Scholar
  41. Kreider MM, Knox S, Gardiner D, Wheadon D (1996) A multicenter doubleblind study of ropinirole as an adjunct to L-dopa in Parkinson’s disease. Neurology 46 [Suppl 2]: 475Google Scholar
  42. Kugler J, Denes G, Groll S, Upmeyer HJ (1990) Behandlung des organischen Psychosyndroms mit Pentifyllin — eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie. Med Welt 41: 1134–1139Google Scholar
  43. Lang C (1989) Medikamentöse Therapie des Par-kinson-Syndroms. Nervenheilkunde 8: 314–317Google Scholar
  44. Langtry HD, Clissold SP (1990) Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 39: 491–506PubMedCrossRefGoogle Scholar
  45. LeBars PL, Katz MM, Berman N, Turan M et al. (1997) A placebo-controlled double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332PubMedCrossRefGoogle Scholar
  46. Lehmann E, VdCrone L, Grobe-Einsler R, Linden M (1993) Drug monitoring phase (Phase IV) of xantinolnicotinate (Complamin registered) in general practice. Pharmacopsychiatry 26: 42–48PubMedCrossRefGoogle Scholar
  47. Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49: 162–168PubMedCrossRefGoogle Scholar
  48. Männistö PT (1994) Clinical potential of catechol O-methyltransferase (COMT) and properties of selective COMT-inhibitors as adjuvants in Parkinson’s disease. CNS Drugs 1: 172–179CrossRefGoogle Scholar
  49. Marsden CD (1998) Clinical experience with ca-bergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs 55 [Suppl 1]: 17–22PubMedCrossRefGoogle Scholar
  50. McNeely W, Davis R (1997) Entacapone. CNS Drugs 8: 79–88CrossRefGoogle Scholar
  51. Mielke R, Kittner B, Ghaemi M, Kessler J et al. (1996) Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. J Neurol Sci 141: 59–64PubMedCrossRefGoogle Scholar
  52. Mierau J, Bedard PJ, Van-Tol HHM, Willner P et al. (1995) Pramipexole: a dopamine-receptor agonist for treatment of Parkinson’s disease. Clin Neuropharmacol 18 [Suppl 1]: 195–206CrossRefGoogle Scholar
  53. Morich FJ, Bieber F, Lewis JM, Kaiser Letal. (1996) Nimodipine in the treatment of probable Alzheimer’s disease. Results of two multicentre trials. Clin Drug Invest 11: 185–195CrossRefGoogle Scholar
  54. Nappi G, Bono G, Merlo P, Borromei A et al. (1997) Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, doubleblind, placebo-controlled study. Clin Drug Invest 13: 308–316CrossRefGoogle Scholar
  55. Olanow CW, Fahn S, Muenter M, Klawans H et al. (1994) A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet registered in Parkinson’s disease. Mov Disord 9: 40–47PubMedCrossRefGoogle Scholar
  56. Olanow CW, Hauser RA, Gauger L, Malapira T et al. (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777PubMedCrossRefGoogle Scholar
  57. Pahwa R, Lyons K, Mcguire D, Silverstein P et al. (1997) Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson’s disease: pharmacokinetic and quality-of-life measures. Mov Disord 12: 677–681PubMedCrossRefGoogle Scholar
  58. Pek G, Fülöp T, Zs-Nagy I (1989) Gerontopsycho-logical studies using NAI („Nürnberger-Alters-Inventar“) on patients with organic psychosyndrome (DSM III, category 1) treated with centrophenoxine in a double blind, comparative randomized clinical trial. Arch Gerontol Geriatr 9: 17–30PubMedCrossRefGoogle Scholar
  59. Rainer M (1997) Galanthamine in Alzheimer’s disease. A new alternative to tacrine? CNS Drugs 7: 89–97CrossRefGoogle Scholar
  60. Riederer P, Umek H (Hrsg) (1986) L-Dopa-Substitution der Parkinson-Krankheit. Springer, Wien New YorkGoogle Scholar
  61. Rieke J, Glaser A (1996) Wirksamkeit und Verträglichkeit von Memantine bei Patienten mit dementiellem Syndrom. Med Welt 47: 251–254Google Scholar
  62. Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339PubMedCrossRefGoogle Scholar
  63. Rösler M, Retz-Junginger P, Retz W (1998) Alzheimer Demenz und Exelon®. Thieme, StuttgartGoogle Scholar
  64. Rother M, Kittner B, Rudolphi K, Rossner M et al. (1996) HWA 285 (propentofylline) — a new Compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Ann NY Acad Sci 777: 404–409PubMedCrossRefGoogle Scholar
  65. Saldmann F, Funel A, Jaquet P (1991) Efficacy of naftidrofuryl in patients with moderate senile dementia. Curr Med Res Opin 12: 379–389PubMedCrossRefGoogle Scholar
  66. Saletu B, Anderer P, Semlitsch HV, Grünberger J et al. (1992) Amantadine infusions in mild dementia: acute double-blind placebo-controlled EEG mapping and psychometric studies. Arch Gerontol Geriatr 15: 43–58PubMedCrossRefGoogle Scholar
  67. Saletu B, Grünberger J, Anderer P, Linzmayer L et al. (1994) Effectkinetics on brain protection of two codergoerine-mesylate preparations (Aramexe retard registered and Hydergine registered) by EEG mapping and psychometry under hypoxia. Arch Gerontol Geriatr 18: 81–99PubMedCrossRefGoogle Scholar
  68. Saletu B, Paulus E, Linzmayer L, Anderer P et al. (1995) Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double blind, placebo controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385–395PubMedCrossRefGoogle Scholar
  69. Schellenberg R, Todorova A, Wedekind W, Schober F et al. (1997) Pathophysiology and psychopharmacology of dementia — a new study design. 2. Cyclandelate treatment — a placebo-controlled double-blind clinical trial. Neuropsychobiology 35: 132–142PubMedCrossRefGoogle Scholar
  70. Schelosky L, Benke T, Poewe WH (1991) Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson’s disease. J Neural Transm [Suppl] 33: 125–132Google Scholar
  71. Schneider E, Fischer PA (1982) Bromocriptin in der Behandlung der fortgeschrittenen Stadien des Parkinson-Syndroms. Dtsch Med Wochenschr 107: 175–179PubMedCrossRefGoogle Scholar
  72. Soholm B (1998) Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. Adv Ther 15: 54–65PubMedGoogle Scholar
  73. Spagnoli A, Tognoni G (1983) Cinnarizine. A brief review of its clinical pharmacology and therapeutic efficacy in cerebrovascular disorders. Drugs 26: 44PubMedCrossRefGoogle Scholar
  74. Spencer CM, Benfield P (1996) Tolcapone. CNS Drugs 5: 475–481CrossRefGoogle Scholar
  75. Spieker S, Loschmann P, Jentgens C, Boose A et al. (1995) Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18: 266–272PubMedCrossRefGoogle Scholar
  76. Spilich GJ, Wannenmacher W, Duarte A, Buendia R et al. (1996) Efficacy of pyritinol versus hydergine upon cognitive performance in patients with senile dementia of the Alzheimer’s type: a double-blind multi-center trial. Alzheimer’s Res 2: 79–84Google Scholar
  77. Steiger MJ, Quinn NP, Marsden CD (1992) The clinical use of apomorphine in Parkinson’s disease. J Neurol 239: 389–393PubMedGoogle Scholar
  78. Tashiro K, Goto I, Kanazawa I, Kowa H et al. (1996) Eight-year follow-up study of bromocriptine monotherapy for Parkinson’s disease. Eur Neurol 36 [Suppl 1]: 32–37PubMedCrossRefGoogle Scholar
  79. Traber J, Gispen WH (eds) (1989) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New YorkGoogle Scholar
  80. Volles E, Friedrich H (1983) Zur Behandlung des Parkinsontremors und isolierter extrapyramidaler Tremorformen mit Metixen. Med Welt 34: 707–709PubMedGoogle Scholar
  81. Wagstaff AJ, Mctavish D (1994) Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in Alzheimer’s disease. Drugs Aging 4: 510–540PubMedCrossRefGoogle Scholar
  82. Wajsbort J, Dorner A, Wajsbort E (1978) A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson’s disease. Curr Med Res Opin 5: 695–708PubMedCrossRefGoogle Scholar
  83. Ward A, Clissold SP (1987) Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 34:50–97PubMedCrossRefGoogle Scholar
  84. Weil C (1989) Hydergin. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  85. Wessel K, Szelenyi I (1992) Selegiline — an overview of its role in the treatment of Parkinson’s disease. Clin Invest 70: 459–462CrossRefGoogle Scholar
  86. Wheadon D, Wilson-Lynch K, Gardiner D, Krei-Der M (1996) The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicent-er double-blind study. Neurology 46 [Suppl 2]: 159Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • O. Dietmaier
  • G. Laux

There are no affiliations available

Personalised recommendations